CAR-T therapies are leading the race to cure cancer

On the Bid is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week.

In this edition, host Oriel Morrison discusses the significant movement in the CAR-T therapies sector in the race to cure cancer 

In this episode Oriel chats to Jennifer Chow, CEO & managing director of Chimeric Therapeutics (ASX:CHM) and Dr Deborah Rathjen, CEO of Carina Biotech. 

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.

Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers.

The panel discuss a range of topics including where we are on the road to finding a cure to cancer, CAR-T treatments, R&D capital and who is paying for it, collaborations in the CAR-T field, what investors can expect from these companies in the next 12 months.

So click above to tune in!